View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Clas...

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; o...

Antoine Legault ... (+2)
  • Antoine Legault
  • Matthew Bryson

Daily Views on Tech Headlines | SNDK, NVDA

While TSMC has exited the GaN space both VIS and GF have licensed TSMC's 650 and 80V technology. We tend to see GF as more likely to realize greater benefits if GaN demand indeed grows at an accelerated pace, given GF's pre-existing efforts in the space, which TSMC's IP only builds upon. We'd also

Dan Salmon
  • Dan Salmon

Meta Platforms (META, Buy, $980 target) Higher revenue guidance oversh...

Our target increases to $980 from $800 on higher estimates. See slide 2-4 for details, and model reflects updated 10K disclosures.

Josseline Jenssen ... (+2)
  • Josseline Jenssen
  • Lorena Reich

Lucror Analytics - Morning Views Latam

In today's Morning Views publication we comment on developments of the following high yield issuers: Gran Tierra Energy, Samarco, Votorantim, GOL, Geopark, Frontera Energy

Lorena Reich
  • Lorena Reich

Gran Tierra Energy - Event Flash - Launches Exchange Offer For Senior ...

Gran Tierra Energy has provided operational and financial updates for Q4 and FY 2025, published its 2025 reserves data and launched an exchange offer for its senior notes due 2029. The results and reserves were below expectations and failed to reach the low end of guidance. In our view, the exchange offer provides a good opportunity for the company to extend the bond duration while having more time to boost production and liquidity.

Stephane Foucaud
  • Stephane Foucaud

AUCTUS ON FRIDAY - 30.01.2026

AUCTUS PUBLICATIONS ________________________________________ Arrow Exploration (AXL LN/CN)C; Target price of £0.40 per share: High production on low decline at Mateguafa – The M-8 well has been brought onstream in the C9 formation (30 ft of oil pay) at 230 bbl/d gross (115 bbl/d net) on a 28/128 choke with 78% water cut. The three C7 intervals did not flow commercial hydrocarbons. The well also encountered 12 ft of net pay in the Gacheta. Although M‑8 is the smallest contributor to field output,...

Pierre FerraguÊ
  • Pierre FerraguÊ

Meta 4Q25: 50% Capex intensity & 40% expense growth - replatforming ov...

Meta reported 4Q25. Please click the link for our updated perspective on hyperscale capex.

Antoine Legault ... (+2)
  • Antoine Legault
  • Matthew Bryson

Daily Views on Tech Headlines | Memory, NVDA, Quantum

We would also point out that to date, China has invested over $15B in its domestic quantum ecosystem, compared to just under $8B in the US (per QED-C State of Global Quantum Industry), once again highlighting the need for additional Federal funding of the US' quantum ecosystem.Given the vested inte

Chase Tohanczyn ... (+4)
  • Chase Tohanczyn
  • Daniel Ives
  • Matthew Weiss
  • Scott Devitt

A Flip of the Script; A Narrative Debunked With Growth; OP, $900 PT

Figure 1. 4Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusNote: 4Q revenue guide in the range of $56-$59B.Meta delivered strong 4Q results. Revenue in the quarter reached $59.9B (+23.8% Y/Y), ahead of consensus of $58.4B (+20.8% Y/Y) by ~3%. Revenue was well above the high

Dan Salmon
  • Dan Salmon

Meta Platforms (META, Buy, $800 target) Huge 1Q26/implied 2026 revenue...

In this first take following tonight’s results, we focus on: 1. Jaw-dropping revenue acceleration trumps heavy investment, easily 2. Ad growth powered by impressions, with solid pricing too 3. 2026 expense guide well above consensus but operating income still growing 4. A wide range for 2026 capex guidance but still above Street

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch